McMillen B A, Scott S M, Williams H L, Sanghera M K
Naunyn Schmiedebergs Arch Pharmacol. 1987 Apr;335(4):454-64. doi: 10.1007/BF00165563.
Gepirone (BMY 13805), a buspirone analog, was used to determine the antianxiety mechanism of the arylpiperazine class of drugs. Because of the weak effects of these drugs on conflict behavior, isolation-induced aggressive mice were used as the antianxiety model. Gepirone, like buspirone, potently inhibited attacks against group housed intruder mice (ED50 = 4.5 mg/kg i.p.) without causing sedation or ataxia. Inhibition of aggression was potentiated by co-administration of 0.25 mg/kg methiothepin or 2.5 mg/kg methysergide. Gepirone had variable effects on dopamine metabolism and reduced 5-hydroxytryptamine (5HT) metabolism about one third after a dose of 2.5 mg/kg. In contrast to buspirone, which markedly increased dopaminergic impulse flow, gepirone inhibited the firing of most cells recorded from the substantia nigra zona compacta in doses of 2.3-10 mg/kg i.v. and the effects were reversible by administration of haloperidol. The common metabolite of buspirone and gepirone, 1-(2-pyrimidinyl)-piperazine, caused increased firing rates only. Gepirone potently inhibited serotonergic impulse flow recorded from the dorsal raphe nucleus (88.3% after 0.04 mg/kg) and this effect was partially reversed by serotonergic antagonists. Both buspirone and gepirone displaced [3H]-5HT from the 5HT1a binding site in the hippocampus with IC50 values of 10 and 58 nM, respectively. Non-alkyl substituted aryl-piperazines displaced [3H]-5HT from both 5HT1a and 5HT1b binding sites. Thus, although gepirone may be a weak postsynaptic 5HT agonist, its primary effect is to decrease 5HT neurotransmission. In support of this conclusion was the observed potentiation of antiaggressive effects by blocking 5HT receptors wit small doses of methiothepin or methysergide, which would exacerbate the decreased release of 5HT caused by gepirone. These results are in harmony with reports that decreased serotonergic activity has anxiolytic-like effects in animal models of anxiety.
吉哌隆(BMY 13805),一种丁螺环酮类似物,被用于确定芳基哌嗪类药物的抗焦虑机制。由于这些药物对冲突行为的影响较弱,因此采用隔离诱导的攻击性小鼠作为抗焦虑模型。吉哌隆与丁螺环酮一样,能有效抑制对群居入侵者小鼠的攻击(腹腔注射半数有效量ED50 = 4.5毫克/千克),且不会引起镇静或共济失调。联合给予0.25毫克/千克甲硫噻平或2.5毫克/千克甲基麦角新碱可增强对攻击行为的抑制作用。吉哌隆对多巴胺代谢有不同影响,在给予2.5毫克/千克剂量后,5-羟色胺(5HT)代谢降低约三分之一。与显著增加多巴胺能冲动发放的丁螺环酮不同,静脉注射2.3 - 10毫克/千克剂量的吉哌隆可抑制黑质致密部记录到的大多数细胞的放电,且给予氟哌啶醇后这种作用可逆转。丁螺环酮和吉哌隆的共同代谢产物1-(2-嘧啶基)-哌嗪仅导致放电频率增加。吉哌隆能有效抑制从背侧中缝核记录到的5-羟色胺能冲动发放(0.04毫克/千克后抑制率为88.3%),且这种作用被5-羟色胺能拮抗剂部分逆转。丁螺环酮和吉哌隆均可从海马体中的5HT1a结合位点置换[3H]-5HT,其半数抑制浓度(IC50)值分别为10和58纳摩尔。非烷基取代的芳基哌嗪可从5HT1a和5HT1b结合位点置换[3H]-5HT。因此,尽管吉哌隆可能是一种较弱的突触后5HT激动剂,但其主要作用是减少5HT神经传递。支持这一结论的是观察到小剂量甲硫噻平或甲基麦角新碱阻断5HT受体可增强抗攻击作用,这会加剧吉哌隆引起的5HT释放减少。这些结果与关于5-羟色胺能活性降低在焦虑动物模型中具有抗焦虑样作用的报道一致。